Search Resources (English): Women and Health Protection (WHP)

Results 21 - 30 of 63

Results

Widespread use of SSRI antidepressants drives soaring health care costs in Canada/What are SSRI antidepressants?  
http://www.cwhn.ca/node/39462
Questions the science behind SSRI antidepressants and their real-world effectiveness. Examines why so many SSRIs are prescribed to women, as well as safety concerns and alternative treatment options. (See Details)
Published: 2006
Drug company funding dominates non-profit organizations, report finds  
http://www.cwhn.ca/node/39464
Provides highlights of a Women and Health Protection report that describes the ways in which drug companies provide funding for health advocacy groups. (See Details)
Published: 2006
Reporting harm caused by medicines  
http://www.whp-apsf.ca/en/documents/adrReport.html
Discusses why women should report all cases of known or suspected harm from prescription drugs and medicines. Provides contact information for consumers who wish to file a report. (See Details)
Published: 2005
Remembering Ruth Cooperstock: women and pharmaceuticals 20 years later  
http://www.whp-apsf.ca/pdf/coopProceedingsEN.pdf
Presents the proceedings of a symposium that examined women and the pharmaceuticals industry. Includes presentations of the three panellists and a brief summary of each of the workshops. (See Details)
Published: 2006
Post-market surveillance of therapeutic drugs in Canada  
http://www.whp-apsf.ca/en/documents/adrBackground.html
Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement. (See Details)
Published: 2005
The inclusion of women in clinical trials: are we asking the right questions?  
http://www.whp-apsf.ca/pdf/clinicalTrialsEN.pdf
Addresses the issues evoked in considering the inclusion of women in clinical trials, highlighting especially where gender, even more than sex, is pertinent. (See Details)
Published: 2006
Illegal direct-to-consumer prescription drug advertising in Canada, 1999 to 2001: when drug companies skirt the law and the gove
Follows a campaign and complaint process regarding direct-to-consumer advertising of prescription drugs.
Published: 2002
Same tune, different lyrics: the Vioxx story  
http://www.cwhn.ca/node/39500
Illustrates the flaws in the Canadian drug approval and drug regulatory processes, using the current Vioxx scandal as example. (See Details)
Published: 2005
CanWest's Charter Challenge on prescription drug advertising: a citizen's guide  
http://www.whp-apsf.ca/pdf/charter_challenge_en.pdf
Discusses the background to this legal case, the implications for Canadians, and what you can do. (See Details)
Published: 2006
How safe are our medicines? Monitoring the risks of drugs after they are approved for marketing  
http://www.whp-apsf.ca/en/documents/how_safe.html
Discusses the drug approval process in Canada, post-approval drug surveillance, adverse drug reactions, and notification of those at risk of harm. Recommends measures to ensure drug safety for Canadian women and their families. (See Details)
Published: 2000